N-MethylcolchicineCAS# 7336-40-5 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 7336-40-5 | SDF | Download SDF |
| PubChem ID | 23758 | Appearance | Powder |
| Formula | C23H27NO6 | M.Wt | 413.5 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | N-methyl-N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide | ||
| SMILES | CC(=O)N(C)C1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC | ||
| Standard InChIKey | AHZFWPXTSZCLDJ-KRWDZBQOSA-N | ||
| Standard InChI | InChI=1S/C23H27NO6/c1-13(25)24(2)17-9-7-14-11-20(28-4)22(29-5)23(30-6)21(14)15-8-10-19(27-3)18(26)12-16(15)17/h8,10-12,17H,7,9H2,1-6H3/t17-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
N-Methylcolchicine Dilution Calculator
N-Methylcolchicine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4184 mL | 12.0919 mL | 24.1838 mL | 48.3676 mL | 60.4595 mL |
| 5 mM | 0.4837 mL | 2.4184 mL | 4.8368 mL | 9.6735 mL | 12.0919 mL |
| 10 mM | 0.2418 mL | 1.2092 mL | 2.4184 mL | 4.8368 mL | 6.0459 mL |
| 50 mM | 0.0484 mL | 0.2418 mL | 0.4837 mL | 0.9674 mL | 1.2092 mL |
| 100 mM | 0.0242 mL | 0.1209 mL | 0.2418 mL | 0.4837 mL | 0.6046 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 2-(4-Methoxybenzal)acetophenone
Catalog No.:BCN0001
CAS No.:959-33-1
- 8-p-Coumaroylharpagide
Catalog No.:BCN0152
CAS No.:87686-74-6
- trans-5-Hydroxyferulic acid
Catalog No.:BCN9999
CAS No.:110642-42-7
- 7-Methoxyflavone
Catalog No.:BCN9998
CAS No.:22395-22-8
- Oxyacanthine hydrochloride
Catalog No.:BCN9997
CAS No.:15352-74-6
- 3,4-Dimethoxychalcone
Catalog No.:BCN9996
CAS No.:5416-71-7
- 2',3,5,7-Tetrahydroxyflavone
Catalog No.:BCN9995
CAS No.:480-15-9
- 4-Hydroxyquinoline
Catalog No.:BCN9994
CAS No.:611-36-9
- Cytochalasin C
Catalog No.:BCN9993
CAS No.:22144-76-9
- Geranylacetate
Catalog No.:BCN9992
CAS No.:105-87-3
- Daclatasvir
Catalog No.:BCN9991
CAS No.:1009119-64-5
- Phloroglucinol aldehyde triethylether
Catalog No.:BCN9990
CAS No.:59652-88-9
- Hydrocotarnine hydrobromide
Catalog No.:BCN0003
CAS No.:5985-00-2
- 8-Acetyl-7-methoxycoumarin
Catalog No.:BCN0004
CAS No.:89019-07-8
- Shatavarin IV
Catalog No.:BCN0005
CAS No.:84633-34-1
- N-trans-p-Coumaroyltyrosine
Catalog No.:BCN0006
CAS No.:77201-66-2
- Chamigrenol
Catalog No.:BCN0007
CAS No.:19822-80-1
- Harmol hydrochloride monohydrate
Catalog No.:BCN0008
CAS No.:40580-83-4
- Daidzein 7-O-glucuronide
Catalog No.:BCN0009
CAS No.:38482-80-3
- Chamaemeloside
Catalog No.:BCN0010
CAS No.:173356-77-9
- Withanoside IV
Catalog No.:BCN0011
CAS No.:362472-81-9
- Phyllanthusiin C
Catalog No.:BCN0012
CAS No.:142674-52-0
- beta-Cryptoxanthin
Catalog No.:BCN0013
CAS No.:472-70-8
- Cyanidin-3-O-rhamnoside chloride
Catalog No.:BCN0014
CAS No.:38533-30-1
In vitro genotoxicity of nitroimidazoles as a tool in the search of new trypanocidal agents.[Pubmed:31271593]
Mem Inst Oswaldo Cruz. 2019;114:e190017.
BACKGROUND: Only benznidazole (Bnz) (1) and nifurtimox (Nfx) (2) are licensed for the treatment of Chagas disease although their safety and efficacy profile are far from ideal. Farmanguinhos from Fiocruz has developed seven nitroimidazole compounds (4-10) analogs of megazol (3). OBJECTIVES: To evaluate whether the genotoxic effect of 3 was abolished in the seven nitroimidazoles (4-10) analogs using the in vitro alkaline comet assay (CA) and the in vitro cytokinesis-block micronucleus assay (CBMN) in whole human blood cells (WHBC) and correlate this effect with their trypanocidal activity using bloodstream trypomastigote forms of Trypanosoma cruzi. METHODS: The toxicity of 3-10 to WHBC in the in vitro CA was determined using the fluorescein diacetate/ethidium bromide assay. DNA damage in the in vitro CA was evaluated according to tail size in four classes (0-3) and methyl methane-sulfonate (MMS) was used as a positive control. The cytotoxicity of 3-10 to WHBC in the CBMN was measured using the cytokinesis-block proliferation index and the replication index. The number of the micronucleate cells in 2,000 binucleate cells by experimental group was determined. Mitomycin C and N-deacetyl-N-Methylcolchicine were used as positive controls. FINDINGS: Compound 3 showed a significant DNA strand break effect through the in vitro CA and highly significant clastogenic and/or aneugenic effect in the CBMN. Compounds 5, 6, 8, 9 and 10 showed negative results in the CBMN and positive results in the in vitro CA, while the inverse effect was observed for 4 and 7. MAIN CONCLUSIONS: Compound 10 was the most promising to proceed with the development as a drug candidate in the treatment of Chagas disease showing absence of chromosomal cytogenetic damage and high activity against T. cruzi, about two times higher than 3 and the clinical drug 1.
Assembly of microtubules at the tip of growing axons.[Pubmed:2872595]
Nature. 1986 Jun 19-25;321(6072):788-90.
The growth of axons in the developing nervous system depends on the elongation of the microtubules that form their principal longitudinal structural element. It is not known whether individual microtubules in the axon elongate at their proximal ends, close to the cell body, and then move forward into the lengthening axon, or whether tubulin subunits are transported to the tip of the axon and assembled there onto the free ends of microtubules. The former possibility is supported by studies of slow axonal transport in mature nerves from which it has been deduced that microtubule assembly occurs principally at the neuronal cell body. By contrast, the polarity of microtubules in axons, which have their 'plus' or 'fast-growing' ends distal to the cell body, suggests that assembly occurs at the growing tip, or growth cone, of the axon. We have addressed this question by topically applying Colcemid (N-desacetyl-N-Methylcolchicine), and other drugs which alter microtubule stability, to different regions of isolated nerve cells growing in tissue culture. We find that the sensitivity to these drugs is greatest at the growth cone by at least two orders of magnitude, suggesting that this is a major site of microtubule assembly during axonal growth.
Mechanism of action of colchicine. I. Effect of colchicine and its analogs on the reversed passive Arthus reaction and the carrageenan-induced hindpaw edema in the rat.[Pubmed:125325]
J Pharmacol Exp Ther. 1975 Jul;194(1):154-8.
Colchicine and N-desacetyl-N-Methylcolchicine suppressed both the reversed passive Arthus reaction and the carrageenan-induced edema in the rat. Colchicine, 2-desmethyl-colchicine glucoside and trimethylcolchicine acid had no effect on either model of inflammation. The ability or inability of these compounds to suppress the development of experimental inflammation correlated with their antimitotic activities. The findings lend support to the hypothesis that the anti-inflammatory and the antimitotic effects of colchicine may depend on the same basic, biophysical mechanism of action, i.e., the disruption of the microtubules.
Colcemid sensitivity of fission yeast and the isolation of colcemid-resistant mutants.[Pubmed:5436084]
Science. 1970 Apr 24;168(3930):485-7.
Cell division of the fission yeast, Schizosaccharomyces pombe, is reversibly inhibited by the antimitotic agent Colcemid (N-deacetyl-N-Methylcolchicine) in nutrient medium. Cell growth continiues until all cells become nonseparating cell doublets in a V configuration. Mutants have been isolated capable of uninhibited growth in the presence of concentrations of Colcemid mycostatic for the parent strain.
